Cardiomyogenic differentiation of human sternal bone marrow mesenchymal stem cells using a combination of basic fibroblast growth factor and hydrocortisone

Pezhman Hafez, Shinsmon Jose, Shiplu Roy Chowdhury, Min Hwei Ng, Ruszymah Idrus, Ramzisham Abdul Rahman Mohd

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The alarming rate of increase in myocardial infarction and marginal success in efforts to regenerate the damaged myocardium through conventional treatments creates an exceptional avenue for cell-based therapy. Adult bone marrow mesenchymal stem cells (MSCs) can be differentiated into cardiomyocytes, by treatment with 5-azacytidine, thus, have been anticipated as a therapeutic tool for myocardial infarction treatment. In this study, we investigated the ability of basic fibroblastic growth factor (bFGF) and hydrocortisone as a combined treatment to stimulate the differentiation of MSCs into cardiomyocytes. MSCs were isolated from sternal marrow of patients undergoing heart surgery (CABG). The isolated cells were initially monitored for the growth pattern, followed by characterization using ISCT recommendations. Cells were then differentiated using a combination of bFGF and hydrocortisone and evaluated for the expression of characteristic cardiac markers such as CTnI, CTnC, and Cnx43 at protein level using immunocytochemistry and flow cytometry, and CTnC and CTnT at mRNA level. The expression levels and pattern of the cardiac markers upon analysis with ICC and qRT-PCR were similar to that of 5-azacytidine induced cells and cultured primary human cardiomyocytes. However, flow cytometric evaluation revealed that induction with bFGF and hydrocortisone drives MSC differentiation to cardiomyocytes with a marginally higher efficiency. These results indicate that combination treatment of bFGF and hydrocortisone can be used as an alternative induction method for cardiomyogenic differentiation of MSCs for future clinical applications.

Original languageEnglish
Pages (from-to)55-64
Number of pages10
JournalCell Biology International
Volume40
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

Fingerprint

Fibroblast Growth Factor 2
Mesenchymal Stromal Cells
Hydrocortisone
Bone Marrow
Cardiac Myocytes
Intercellular Signaling Peptides and Proteins
Azacitidine
Therapeutics
Myocardial Infarction
Cell- and Tissue-Based Therapy
Thoracic Surgery
Cell Differentiation
Cultured Cells
Myocardium
Flow Cytometry
Immunohistochemistry
Polymerase Chain Reaction
Messenger RNA
Growth
Proteins

Keywords

  • basic fibroblast growth factor
  • cardiomyocytes
  • human mesenchymal stem cells
  • hydrocortisone

ASJC Scopus subject areas

  • Cell Biology

Cite this

Cardiomyogenic differentiation of human sternal bone marrow mesenchymal stem cells using a combination of basic fibroblast growth factor and hydrocortisone. / Hafez, Pezhman; Jose, Shinsmon; Chowdhury, Shiplu Roy; Ng, Min Hwei; Idrus, Ruszymah; Abdul Rahman Mohd, Ramzisham.

In: Cell Biology International, Vol. 40, No. 1, 01.01.2016, p. 55-64.

Research output: Contribution to journalArticle

@article{ed70c0ccfff44f2fae134a10115d3906,
title = "Cardiomyogenic differentiation of human sternal bone marrow mesenchymal stem cells using a combination of basic fibroblast growth factor and hydrocortisone",
abstract = "The alarming rate of increase in myocardial infarction and marginal success in efforts to regenerate the damaged myocardium through conventional treatments creates an exceptional avenue for cell-based therapy. Adult bone marrow mesenchymal stem cells (MSCs) can be differentiated into cardiomyocytes, by treatment with 5-azacytidine, thus, have been anticipated as a therapeutic tool for myocardial infarction treatment. In this study, we investigated the ability of basic fibroblastic growth factor (bFGF) and hydrocortisone as a combined treatment to stimulate the differentiation of MSCs into cardiomyocytes. MSCs were isolated from sternal marrow of patients undergoing heart surgery (CABG). The isolated cells were initially monitored for the growth pattern, followed by characterization using ISCT recommendations. Cells were then differentiated using a combination of bFGF and hydrocortisone and evaluated for the expression of characteristic cardiac markers such as CTnI, CTnC, and Cnx43 at protein level using immunocytochemistry and flow cytometry, and CTnC and CTnT at mRNA level. The expression levels and pattern of the cardiac markers upon analysis with ICC and qRT-PCR were similar to that of 5-azacytidine induced cells and cultured primary human cardiomyocytes. However, flow cytometric evaluation revealed that induction with bFGF and hydrocortisone drives MSC differentiation to cardiomyocytes with a marginally higher efficiency. These results indicate that combination treatment of bFGF and hydrocortisone can be used as an alternative induction method for cardiomyogenic differentiation of MSCs for future clinical applications.",
keywords = "basic fibroblast growth factor, cardiomyocytes, human mesenchymal stem cells, hydrocortisone",
author = "Pezhman Hafez and Shinsmon Jose and Chowdhury, {Shiplu Roy} and Ng, {Min Hwei} and Ruszymah Idrus and {Abdul Rahman Mohd}, Ramzisham",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/cbin.10536",
language = "English",
volume = "40",
pages = "55--64",
journal = "Cell Biology International",
issn = "1065-6995",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Cardiomyogenic differentiation of human sternal bone marrow mesenchymal stem cells using a combination of basic fibroblast growth factor and hydrocortisone

AU - Hafez, Pezhman

AU - Jose, Shinsmon

AU - Chowdhury, Shiplu Roy

AU - Ng, Min Hwei

AU - Idrus, Ruszymah

AU - Abdul Rahman Mohd, Ramzisham

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The alarming rate of increase in myocardial infarction and marginal success in efforts to regenerate the damaged myocardium through conventional treatments creates an exceptional avenue for cell-based therapy. Adult bone marrow mesenchymal stem cells (MSCs) can be differentiated into cardiomyocytes, by treatment with 5-azacytidine, thus, have been anticipated as a therapeutic tool for myocardial infarction treatment. In this study, we investigated the ability of basic fibroblastic growth factor (bFGF) and hydrocortisone as a combined treatment to stimulate the differentiation of MSCs into cardiomyocytes. MSCs were isolated from sternal marrow of patients undergoing heart surgery (CABG). The isolated cells were initially monitored for the growth pattern, followed by characterization using ISCT recommendations. Cells were then differentiated using a combination of bFGF and hydrocortisone and evaluated for the expression of characteristic cardiac markers such as CTnI, CTnC, and Cnx43 at protein level using immunocytochemistry and flow cytometry, and CTnC and CTnT at mRNA level. The expression levels and pattern of the cardiac markers upon analysis with ICC and qRT-PCR were similar to that of 5-azacytidine induced cells and cultured primary human cardiomyocytes. However, flow cytometric evaluation revealed that induction with bFGF and hydrocortisone drives MSC differentiation to cardiomyocytes with a marginally higher efficiency. These results indicate that combination treatment of bFGF and hydrocortisone can be used as an alternative induction method for cardiomyogenic differentiation of MSCs for future clinical applications.

AB - The alarming rate of increase in myocardial infarction and marginal success in efforts to regenerate the damaged myocardium through conventional treatments creates an exceptional avenue for cell-based therapy. Adult bone marrow mesenchymal stem cells (MSCs) can be differentiated into cardiomyocytes, by treatment with 5-azacytidine, thus, have been anticipated as a therapeutic tool for myocardial infarction treatment. In this study, we investigated the ability of basic fibroblastic growth factor (bFGF) and hydrocortisone as a combined treatment to stimulate the differentiation of MSCs into cardiomyocytes. MSCs were isolated from sternal marrow of patients undergoing heart surgery (CABG). The isolated cells were initially monitored for the growth pattern, followed by characterization using ISCT recommendations. Cells were then differentiated using a combination of bFGF and hydrocortisone and evaluated for the expression of characteristic cardiac markers such as CTnI, CTnC, and Cnx43 at protein level using immunocytochemistry and flow cytometry, and CTnC and CTnT at mRNA level. The expression levels and pattern of the cardiac markers upon analysis with ICC and qRT-PCR were similar to that of 5-azacytidine induced cells and cultured primary human cardiomyocytes. However, flow cytometric evaluation revealed that induction with bFGF and hydrocortisone drives MSC differentiation to cardiomyocytes with a marginally higher efficiency. These results indicate that combination treatment of bFGF and hydrocortisone can be used as an alternative induction method for cardiomyogenic differentiation of MSCs for future clinical applications.

KW - basic fibroblast growth factor

KW - cardiomyocytes

KW - human mesenchymal stem cells

KW - hydrocortisone

UR - http://www.scopus.com/inward/record.url?scp=85007356415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007356415&partnerID=8YFLogxK

U2 - 10.1002/cbin.10536

DO - 10.1002/cbin.10536

M3 - Article

C2 - 26289249

AN - SCOPUS:85007356415

VL - 40

SP - 55

EP - 64

JO - Cell Biology International

JF - Cell Biology International

SN - 1065-6995

IS - 1

ER -